Stay updated on Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial

Sign up to get notified when there's something new on the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    Revision updated to v3.5.2, replacing the previous v3.5.0.
    Difference
    0.0%
    Check dated 2026-04-16T10:44:32.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    38 days ago
    Change Detected
    Summary
    Revision updated to v3.5.0. The previous revision v3.4.3 was removed.
    Difference
    0.0%
    Check dated 2026-03-18T18:02:31.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-11T15:25:35.000Z thumbnail image
  6. Check
    74 days ago
    Change Detected
    Summary
    Study status updated to Completed with 137 participants enrolled and a completion date of 2026-01-28, with the record revision to v3.4.2. The previous funding notice and the 'Active, not recruiting' indicator were removed.
    Difference
    0.7%
    Check dated 2026-02-11T09:27:03.000Z thumbnail image
  7. Check
    81 days ago
    Change Detected
    Summary
    Added a site-wide notice about a lapse in government funding, stating the NIH Clinical Center is open and directing users to cc.nih.gov and opm.gov for status updates. Updated the system revision from v3.4.0 to v3.4.1.
    Difference
    0.3%
    Check dated 2026-02-04T05:39:08.000Z thumbnail image
  8. Check
    88 days ago
    Change Detected
    Summary
    The page now includes a glossary toggle and updated QC-related labels and revision information (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0), replacing the previous labels and version (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4).
    Difference
    0.2%
    Check dated 2026-01-28T03:55:19.000Z thumbnail image

Stay in the know with updates to Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page.